Skip to main content
SpringerLink
Log in
Book cover

Arrestins - Pharmacology and Therapeutic Potential pp 405–425Cite as

Arrestins as Regulatory Hubs in Cancer Signalling Pathways

  • Chapter
  • First Online:

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 219))

Abstract

Non-visual arrestins were initially appreciated for the roles they play in the negative regulation of G protein-coupled receptors through the processes of desensitisation and endocytosis. The arrestins are also now known as protein scaffolding platforms that act downstream of multiple types of receptors, ensuring relevant transmission of information for an appropriate cellular response. They function as regulatory hubs in several important signalling pathways that are often dysregulated in human cancers. Interestingly, several recent studies have documented changes in expression and localisation of arrestins that occur during cancer progression and that correlate with clinical outcome. Here, we discuss these advances and how changes in expression/localisation may affect functional outputs of arrestins in cancer biology.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Archacki SR, Angheloiu G, Tian XL, Tan FL, DiPaola N, Shen GQ, Moravec C, Ellis S, Topol EJ, Wang Q (2003) Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics 15:65–74

    CAS  PubMed  Google Scholar 

  • Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG, Lefkowitz RJ (1992) beta-Arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267:17882–17890

    CAS  PubMed  Google Scholar 

  • Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171–179

    Article  CAS  PubMed  Google Scholar 

  • Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273

    Article  CAS  PubMed  Google Scholar 

  • Bonnans C, Flaceliere M, Grillet F, Dantec C, Desvignes JP, Pannequin J, Severac D, Dubois E, Bibeau F, Escriou V, Crespy P, Journot L, Hollande F, Joubert D (2012) Essential requirement for beta-arrestin2 in mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci USA 109:3047–3052

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Boularan C, Scott MG, Bourougaa K, Bellal M, Esteve E, Thuret A, Benmerah A, Tramier M, Coppey-Moisan M, Labbe-Jullie C, Fahraeus R, Marullo S (2007) beta-Arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53. Proc Natl Acad Sci USA 104:18061–18066

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bryja V, Gradl D, Schambony A, Arenas E, Schulte G (2007) Beta-arrestin is a necessary component of Wnt/beta-catenin signaling in vitro and in vivo. Proc Natl Acad Sci USA 104:6690–6695

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103:1492–1497

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV (2008) Arrestins and two receptor kinases are upregulated in Parkinson’s disease with dementia. Neurobiol Aging 29:379–396

    Article  CAS  PubMed  Google Scholar 

  • Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127–150

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chen W, Hu LA, Semenov MV, Yanagawa S, Kikuchi A, Lefkowitz RJ, Miller WE (2001) beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc Natl Acad Sci USA 98:14889–14894

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chuensumran U, Wongkham S, Pairojkul C, Chauin S, Petmitr S (2007) Prognostic value of DNA alterations on chromosome 17p13.2 for intrahepatic cholangiocarcinoma. World J Gastroenterol 13:2986–2991

    CAS  PubMed  Google Scholar 

  • Chun KS, Lao HC, Trempus CS, Okada M, Langenbach R (2009) The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis 30:1620–1627

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Crotty TM, Nakano T, Stafforini DM, Topham MK (2013) Diacylglycerol kinase delta modulates Akt phosphorylation through pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2). J Biol Chem 288:1439–1447

    Article  CAS  PubMed  Google Scholar 

  • Dalle S, Imamura T, Rose DW, Worrall DS, Ugi S, Hupfeld CJ, Olefsky JM (2002) Insulin induces heterologous desensitization of G-protein-coupled receptor and insulin-like growth factor I signaling by downregulating beta-arrestin-1. Mol Cell Biol 22:6272–6285

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E, Chellappan SP (2011) ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst 103:317–333

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Dawson TM, Arriza JL, Jaworsky DE, Borisy FF, Attramadal H, Lefkowitz RJ, Ronnett GV (1993) Beta-adrenergic receptor kinase-2 and beta-arrestin-2 as mediators of odorant-induced desensitization. Science 259:825–829

    Article  CAS  PubMed  Google Scholar 

  • DeFea KA (2007) Stop that cell! Beta-arrestin-dependent chemotaxis: a tale of localized actin assembly and receptor desensitization. Annu Rev Physiol 69:535–560

    Article  CAS  PubMed  Google Scholar 

  • DeFea KA (2011) Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell Signal 23:621–629

    Article  CAS  PubMed  Google Scholar 

  • DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW (2000a) beta-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148:1267–1281

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • DeFea KA, Vaughn ZD, O’Bryan EM, Nishijima D, Dery O, Bunnett NW (2000b) The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97:11086–11091

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483–510

    Article  CAS  PubMed  Google Scholar 

  • Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38:698–707

    Article  CAS  PubMed  Google Scholar 

  • Fereshteh M, Ito T, Kovacs JJ, Zhao C, Kwon HY, Tornini V, Konuma T, Chen M, Lefkowitz RJ, Reya T (2012) beta-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci USA 109:12532–12537

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gavard J, Gutkind JS (2006) VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8:1223–1234

    Article  CAS  PubMed  Google Scholar 

  • Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, Larsson O (2005) {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 280:24412–24419

    Article  CAS  PubMed  Google Scholar 

  • Goel R, Phillips-Mason PJ, Raben DM, Baldassare JJ (2002) alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression. J Biol Chem 277:18640–18648

    Article  CAS  PubMed  Google Scholar 

  • Golan M, Schreiber G, Avissar S (2010) Antidepressants increase beta-arrestin 2 ubiquitinylation and degradation by the proteasomal pathway in C6 rat glioma cells. J Pharmacol Exp Ther 332:970–976

    Article  CAS  PubMed  Google Scholar 

  • Gurevich EV, Gurevich VV (2006) Arrestins: ubiquitous regulators of cellular signaling pathways. Genome Biol 7:236

    Article  PubMed Central  PubMed  Google Scholar 

  • Gurevich VV, Gurevich EV (2012) Synthetic biology with surgical precision: targeted reengineering of signaling proteins. Cell Signal 24:1899–1908

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gurevich EV, Benovic JL, Gurevich VV (2002) Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109:421–436

    Article  CAS  PubMed  Google Scholar 

  • Gurevich EV, Benovic JL, Gurevich VV (2004) Arrestin2 expression selectively increases during neural differentiation. J Neurochem 91:1404–1416

    Article  CAS  PubMed  Google Scholar 

  • Gurevich VV, Gurevich EV, Cleghorn WM (2008) Arrestins as multi-functional signaling adaptors. Handb Exp Pharmacol 15–37

    Google Scholar 

  • Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, Shenoy SK, Gregory SG, Ahn S, Duckett DR, Lefkowitz RJ (2011) A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 477:349–353

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hoeppner CZ, Cheng N, Ye RD (2012) Identification of a nuclear localization sequence in beta-arrestin-1 and its functional implications. J Biol Chem 287:8932–8943

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Houben AJ, Moolenaar WH (2011) Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 30:557–565

    Article  CAS  PubMed  Google Scholar 

  • Hupfeld CJ, Dalle S, Olefsky JM (2003) beta-Arrestin 1 down-regulation after insulin treatment is associated with supersensitization of beta 2 adrenergic receptor Galpha s signaling in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 100:161–166

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, Zhang M, Bao G, Wang F, Zhang X, Yang R, Fan F, Chen X, Pei G, Ma L (2005) A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123:833–847

    Article  CAS  PubMed  Google Scholar 

  • Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ (2009) Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 17:443–458

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, Benovic JL, Daaka Y (2009) Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA 106:9379–9384

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, Mills GB, Babwah AV, Bhattacharya M (2009) Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7:1064–1077

    Article  CAS  PubMed  Google Scholar 

  • Lima-Fernandes E, Enslen H, Camand E, Kotelevets L, Boularan C, Achour L, Benmerah A, Gibson LC, Baillie GS, Pitcher JA, Chastre E, Etienne-Manneville S, Marullo S, Scott MG (2011) Distinct functional outputs of PTEN signalling are controlled by dynamic association with beta-arrestins. EMBO J 30:2557–2568

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Liu H, Long J, Zhang PH, Li K, Tan JJ, Sun B, Yu J, Tu ZG, Zou L (2011) Elevated beta-arrestin1 expression correlated with risk stratification in acute lymphoblastic leukemia. Int J Hematol 93:494–501

    Article  CAS  PubMed  Google Scholar 

  • Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF, Camina JP (2009) c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and -dependent mechanisms. PLoS One 4:e4686

    Google Scholar 

  • Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G (2009) Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457:1146–1149

    Article  CAS  PubMed  Google Scholar 

  • Lundgren K, Tobin NP, Lehn S, Stal O, Ryden L, Jirstrom K, Landberg G (2011) Stromal expression of beta-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer. J Mol Diagn 13:340–351

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Luttrell LM, Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305–330

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655–661

    Article  CAS  PubMed  Google Scholar 

  • Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ (2001) Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA 98:2449–2454

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ma L, Pei G (2007) Beta-arrestin signaling and regulation of transcription. J Cell Sci 120:213–218

    Article  CAS  PubMed  Google Scholar 

  • Mandell JW, Glass G, Gianchandani EP, Locke CN, Amos S, Bourne TD, Schiff D, Papin JA (2009) Dephosphorylation of beta-arrestin 1 in glioblastomas. J Neuropathol Exp Neurol 68:535–541

    Article  CAS  PubMed  Google Scholar 

  • Manson ME, Corey DA, White NM, Kelley TJ (2008) cAMP-mediated regulation of cholesterol accumulation in cystic fibrosis and Niemann-Pick type C cells. Am J Physiol Lung Cell Mol Physiol 295:L809–L819

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Matuzany-Ruban A, Avissar S, Schreiber G (2005) Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. J Affect Disord 88:307–312

    Article  CAS  PubMed  Google Scholar 

  • Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL (2011) Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Res Treat 130:791–807

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Milano SK, Kim YM, Stefano FP, Benovic JL, Brenner C (2006) Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding. J Biol Chem 281:9812–9823

    Article  CAS  PubMed  Google Scholar 

  • Min J, Defea K (2011) beta-Arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol 80:760–768

    Article  CAS  PubMed  Google Scholar 

  • Moore CA, Milano SK, Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451–482

    Article  CAS  PubMed  Google Scholar 

  • Mythreye K, Blobe GC (2009) The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106:8221–8226

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Oakley RH, Revollo J, Cidlowski JA (2012) Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptors. Proc Natl Acad Sci USA 109:17591–17596

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Parruti G, Peracchia F, Sallese M, Ambrosini G, Masini M, Rotilio D, De Blasi A (1993) Molecular analysis of human beta-arrestin-1: cloning, tissue distribution, and regulation of expression. Identification of two isoforms generated by alternative splicing. J Biol Chem 268:9753–9761

    CAS  PubMed  Google Scholar 

  • Povsic TJ, Kohout TA, Lefkowitz RJ (2003) Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278:51334–51339

    Article  CAS  PubMed  Google Scholar 

  • Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM (2008) Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 180:5699–5706

    CAS  PubMed  Google Scholar 

  • Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106:2806–2811

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A (2012) beta-Arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling. Oncogene. doi:10.1038/onc.2012.527

    Google Scholar 

  • Schaffner F, Ruf W (2009) Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 29:1999–2004

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schulte G, Schambony A, Bryja V (2010) beta-Arrestins - scaffolds and signalling elements essential for WNT/Frizzled signalling pathways? Br J Pharmacol 159:1051–1058

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S, Marullo S, Benmerah A (2002) Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem 277:37693–37701

    Article  CAS  PubMed  Google Scholar 

  • Scott MG, Pierotti V, Storez H, Lindberg E, Thuret A, Muntaner O, Labbe-Jullie C, Pitcher JA, Marullo S (2006) Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and beta-arrestins. Mol Cell Biol 26:3432–3445

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ (2001) Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294:1307–1313

    Article  CAS  PubMed  Google Scholar 

  • Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, Dewhirst MW (2012) beta-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene 31:282–292

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shukla AK, Xiao K, Lefkowitz RJ (2011) Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 36:457–469

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Song X, Raman D, Gurevich EV, Vishnivetskiy SA, Gurevich VV (2006) Visual and both non-visual arrestins in their “inactive” conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm. J Biol Chem 281:21491–21499

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sterne-Marr R, Gurevich VV, Goldsmith P, Bodine RC, Sanders C, Donoso LA, Benovic JL (1993) Polypeptide variants of beta-arrestin and arrestin3. J Biol Chem 268:15640–15648

    CAS  PubMed  Google Scholar 

  • Thathiah A, Horre K, Snellinx A, Vandewyer E, Huang Y, Ciesielska M, De Kloe G, Munck S, De Strooper B (2013) beta-Arrestin 2 regulates Abeta generation and gamma-secretase activity in Alzheimer’s disease. Nat Med 19:43–49

    Article  CAS  PubMed  Google Scholar 

  • Wang P, Wu Y, Ge X, Ma L, Pei G (2003a) Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 278:11648–11653

    Article  CAS  PubMed  Google Scholar 

  • Wang P, Gao H, Ni Y, Wang B, Wu Y, Ji L, Qin L, Ma L, Pei G (2003b) beta-Arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 278:6363–6370

    Article  CAS  PubMed  Google Scholar 

  • Wang P, Kumar P, Wang C, Defea KA (2007) Differential regulation of class IA phosphoinositide 3-kinase catalytic subunits p110 alpha and beta by protease-activated receptor 2 and beta-arrestins. Biochem J 408:221–230

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, Yates JR 3rd, Lefkowitz RJ (2007) Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 104:12011–12016

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang P, He X, Tan J, Zhou X, Zou L (2011) beta-arrestin2 mediates beta-2 adrenergic receptor signaling inducing prostate cancer cell progression. Oncol Rep 26:1471–1477

    CAS  PubMed  Google Scholar 

  • Zou L, Yang R, Chai J, Pei G (2008) Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 22:355–364

    Article  CAS  PubMed  Google Scholar 

  • Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA (2007) Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem 282:20634–20646

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We apologise to the many authors who could not be cited due to space restrictions and thank Dr S. Marullo for helpful discussions. The laboratory is part of the multidisciplinary “Who am I?” LABEX. This work was supported by the Fondation ARC pour la Recherche sur le Cancer, Ligue Contre le Cancer (comité de l’Oise), Fondation pour la Recherche Biomedicale (“Equipe FRM”), CNRS and INSERM. ELF was funded by a doctoral fellowship from the Fondation ARC pour la Recherche sur le Cancer and subsequently a postdoctoral fellowship from the National Research Fund, Luxembourg, co-funded under the Marie Curie Actions of the European Commission (FP7-COFUND).

Author information

Authors and Affiliations

  1. Inserm, U1016, Institut Cochin, 27, Rue du Faubourg Saint Jacques, 75014, Paris, France

    Hervé Enslen, Evelyne Lima-Fernandes & Mark G. H. Scott

  2. CNRS, UMR8104, Paris, France

    Hervé Enslen, Evelyne Lima-Fernandes & Mark G. H. Scott

  3. Univ. Paris Descartes, Sorbonne Paris Cité, Paris, France

    Hervé Enslen, Evelyne Lima-Fernandes & Mark G. H. Scott

  4. Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada

    Evelyne Lima-Fernandes

Authors
  1. Hervé Enslen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evelyne Lima-Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark G. H. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hervé Enslen or Mark G. H. Scott .

Editor information

Editors and Affiliations

  1. Professor of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Vsevolod V. Gurevich

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Enslen, H., Lima-Fernandes, E., Scott, M.G.H. (2014). Arrestins as Regulatory Hubs in Cancer Signalling Pathways. In: Gurevich, V. (eds) Arrestins - Pharmacology and Therapeutic Potential. Handbook of Experimental Pharmacology, vol 219. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41199-1_21

Download citation

Publish with us

Policies and ethics

Search

Navigation